KR101742332B1 - 생체분자로 세포를 형질감염시키기 위한 조성물 - Google Patents

생체분자로 세포를 형질감염시키기 위한 조성물 Download PDF

Info

Publication number
KR101742332B1
KR101742332B1 KR1020117027684A KR20117027684A KR101742332B1 KR 101742332 B1 KR101742332 B1 KR 101742332B1 KR 1020117027684 A KR1020117027684 A KR 1020117027684A KR 20117027684 A KR20117027684 A KR 20117027684A KR 101742332 B1 KR101742332 B1 KR 101742332B1
Authority
KR
South Korea
Prior art keywords
biologically active
peptide
rti
biopolymer carrier
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117027684A
Other languages
English (en)
Korean (ko)
Other versions
KR20120109291A (ko
Inventor
피터 그랜딕스
수잔 스자스마리
Original Assignee
갈렌바이오 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈렌바이오 인코포레이티드 filed Critical 갈렌바이오 인코포레이티드
Publication of KR20120109291A publication Critical patent/KR20120109291A/ko
Application granted granted Critical
Publication of KR101742332B1 publication Critical patent/KR101742332B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117027684A 2009-04-20 2010-04-19 생체분자로 세포를 형질감염시키기 위한 조성물 Expired - Fee Related KR101742332B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17094509P 2009-04-20 2009-04-20
US61/170,945 2009-04-20
PCT/US2010/031559 WO2010123798A2 (en) 2009-04-20 2010-04-19 Compositions for transfection of biomolecules into cells

Publications (2)

Publication Number Publication Date
KR20120109291A KR20120109291A (ko) 2012-10-08
KR101742332B1 true KR101742332B1 (ko) 2017-05-31

Family

ID=43011700

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117027684A Expired - Fee Related KR101742332B1 (ko) 2009-04-20 2010-04-19 생체분자로 세포를 형질감염시키기 위한 조성물

Country Status (7)

Country Link
US (1) US11738084B2 (enExample)
EP (1) EP2421952B1 (enExample)
JP (2) JP6101077B2 (enExample)
KR (1) KR101742332B1 (enExample)
AU (1) AU2010239463B2 (enExample)
HU (1) HUE028642T2 (enExample)
WO (1) WO2010123798A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
JP6208767B2 (ja) * 2012-10-23 2017-10-04 エコール スペリュール デ フィジーク エ シミ アンドゥストリエル デ ラ ヴィル デ パリ 複数回逐次的に形成し、切断することができる可逆的共有結合を含む粒子
CN103849650B (zh) * 2013-10-14 2018-08-03 王深明 功能化纳米姜黄素的基因导入材料及制备方法
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
SG11201805375PA (en) 2016-02-04 2018-07-30 Stem Cell Theranostics Inc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
CN108330102B (zh) * 2018-03-14 2020-02-14 江南大学 一株泰妙菌素单克隆抗体杂交瘤细胞株及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081576A2 (en) 2005-01-28 2006-08-03 Galenbio, Inc. Immunologically active compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954515A (enExample) 1972-10-03 1974-05-27
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
JP2524406B2 (ja) * 1988-07-05 1996-08-14 田辺製薬株式会社 パイロジェン定量方法
KR100191223B1 (ko) * 1989-07-28 1999-06-15 둘락 노먼 씨. 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
JPH10510433A (ja) 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6194469B1 (en) 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
ES2243229T3 (es) * 1999-02-03 2005-12-01 Powderject Res Ltd Formulaciones de particulas de hidrogel.
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
AU2001273128C1 (en) * 2000-06-29 2006-09-21 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
ES2263859T3 (es) * 2003-02-18 2006-12-16 Clinique La Prairie Research Sa Composiciones qu4e comprenden hemoglobina fetal y endotoxina bacteriana y opcionalmente componentes de higado fetal adicionales.
US7785769B2 (en) * 2003-07-25 2010-08-31 The United States of America as reprsented by the Secretary of the Navy Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
US20070281036A1 (en) * 2005-12-19 2007-12-06 University Of Vermont And State Agricultural College System and method of delivering a desired material to a cell
US8288124B2 (en) * 2008-11-20 2012-10-16 Abbott Laboratories Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay
JP6101077B2 (ja) * 2009-04-20 2017-03-22 ガレンバイオ、インコーポレイテッド 生体分子を細胞へトランスフェクトするための組成物
ES2397909B1 (es) * 2011-05-05 2014-06-06 Universidad De Zaragoza Procedimiento de obtención de materiales multifuncionalizados

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081576A2 (en) 2005-01-28 2006-08-03 Galenbio, Inc. Immunologically active compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Szathmary Susan, "immunomodulation of pathogen-host iteractions," Szent Istvan University (2015.01.01.)

Also Published As

Publication number Publication date
EP2421952A2 (en) 2012-02-29
US11738084B2 (en) 2023-08-29
EP2421952B1 (en) 2016-03-30
JP6295235B2 (ja) 2018-03-14
KR20120109291A (ko) 2012-10-08
HUE028642T2 (en) 2016-12-28
JP2016027048A (ja) 2016-02-18
JP6101077B2 (ja) 2017-03-22
WO2010123798A3 (en) 2011-03-10
AU2010239463B2 (en) 2016-12-08
AU2010239463A1 (en) 2011-12-08
JP2012524120A (ja) 2012-10-11
US20130095124A1 (en) 2013-04-18
CN102575225A (zh) 2012-07-11
WO2010123798A2 (en) 2010-10-28
EP2421952A4 (en) 2013-03-06

Similar Documents

Publication Publication Date Title
JP6295235B2 (ja) 生体分子を細胞へトランスフェクトするための組成物
Juodeikis et al. Outer membrane vesicles: biogenesis, functions, and issues
Tse Sum Bui et al. Fighting Antibiotic‐Resistant Bacteria: Promising Strategies Orchestrated by Molecularly Imprinted Polymers
Ezzat Alnakip et al. The immunology of mammary gland of dairy ruminants between healthy and inflammatory conditions
CN115697390B (zh) 一种肿瘤疫苗及其制备方法和应用
EP2477641B1 (en) Inhibition of endosomal toll-like receptor activation for treating thrombotic disorders
Nabergoj et al. Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy
Ciaston et al. Proteolytic activity-independent activation of the immune response by gingipains from Porphyromonas gingivalis
US20220259254A1 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20230355689A1 (en) Solid dosage forms containing bacteria and microbial extracellular vesicles
EP3525802B1 (en) Cancer stem cell exosomes
Gang Liu et al. Abrogation of cathepsin C by Helicobacter pylori impairs neutrophil activation to promote gastric infection
Chen et al. Recent advances in biomedical applications of bacterial outer membrane vesicles
Knotigová et al. Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity
Aganja et al. Safety assessment of compliant, highly invasive, lipid A-altered, O-antigen-defected Salmonella strains as prospective vaccine delivery systems
Heuking et al. Fate of TLR-1/TLR-2 agonist functionalised pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro
KR20070114727A (ko) 면역학적 활성 조성물
CN102575225B (zh) 用于将生物分子转染进细胞的组合物
US20240423924A1 (en) Prevotella extracellular vesicle preparations
Cai et al. Bacteria‐Derived Extracellular Vesicle as A “Trojan Horse” for Selective M1 Macrophage‐Targeting in A Multi‐Cellular Entanglement Environment
Yelyseyeva et al. Anti-adhesive therapies as a contemporary means to fight infectious diseases and adherence factors of Corynebacteria diphtheriae
US20240148797A1 (en) Compositions and methods for reducing cytokine expression
US20250049951A1 (en) Nucleic acid compositions and uses thereof
Brohlin Polymeric Encapsulation of Vaccines for Enhanced Immunogenicity
Holani Immunomodulatory Role of Cathelicidin at Colonic Epithelium

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220526

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220526